Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CTH | P32929 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25247941 | 0.86 | ALDH1A1 (0.47) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL29377788 | 0.86 | ALDH1A1 (0.47) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL2201841 | 0.86 | CA12 (0.54) | ALDH1A1MAPTLMNACA12CA1 | |
| SCHEMBL29380452 | 0.84 | CTSB (0.44) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL25251862 | 0.84 | CTSB (0.44) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL26245033 | 0.82 | CTSB (0.55) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL25248706 | 0.81 | HSP90AA1 (0.48) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL30275435 | 0.81 | HSP90AA1 (0.48) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL27190092 | 0.81 | MAOB (0.53) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL25298744 | 0.80 | CTSB (0.56) | KMT2AALDH1A1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | Jiangsu Yahong Meditech Co. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4194441-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194441-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-115867540-A | Nitroxoline derivatives, preparation method and application thereof | 江苏亚虹医药科技股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022028321-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | NOS1, NQO1, NOS2 | KMT2A 3512/4885ALDH1A1 752/4885MAPT 3319/4885 |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOS1, NQO1, NOS2 | KMT2A 3512/4885ALDH1A1 752/4885MAPT 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.